Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Viruses

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    341 result(s) found for: Viruses. Displaying page 8 of 18.
    EudraCT Number: 2020-002713-17 Sponsor Protocol Number: GA42469 Start Date*: 2020-07-13
    Sponsor Name:Genentech, Inc.
    Full Title: A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MSTT1041A OR UTTR1147A IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA
    Medical condition: Severe coronavirus disease 2019 (COVID-19) pneumonia
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004862 10084383 Novel COVID-19-infected pneumonia LLT
    23.0 100000004862 10084270 SARS-CoV-2 acute respiratory disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2013-003978-27 Sponsor Protocol Number: GS-US-337-1119 Start Date*: 2014-02-20
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2, Multicenter, Open-Label Study to Investigate the Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination in Treatment-Naïve and Treatment-Experienced Subjects with Chronic Ge...
    Medical condition: Chronic Genotype 4 and Genotype 5 Hepatitis C Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004848 10019751 Hepatitis C virus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-022092-65 Sponsor Protocol Number: ACH625-003 Start Date*: 2011-10-13
    Sponsor Name:Achillion Pharmaceuticals, Inc.
    Full Title: A phase IIa, randomized, double-blind (subject and investigator blind, sponsor open) placebo-controlled trial to evaluate the safety, tolerability and antiviral activity of oral ACH-0141625 in comb...
    Medical condition: Hepatitis C Virus Genotype 1
    Disease: Version SOC Term Classification Code Term Level
    14.0 10022891 - Investigations 10019751 Hepatitis C virus LLT
    14.0 10021881 - Infections and infestations 10019744 Hepatitis C PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2022-003339-24 Sponsor Protocol Number: DEN-308 Start Date*: 2022-12-21
    Sponsor Name:Takeda Vaccines, Inc.
    Full Title: A Phase 3, Open-Label, Randomized Trial to Investigate the Immunogenicity and Safety of the Co-administration of a Subcutaneous Dengue Tetravalent Vaccine (Live, Attenuated) (TDV) and an Intramuscu...
    Medical condition: Dengue fever
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004862 10012312 Dengue fever virus infection LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-004541-33 Sponsor Protocol Number: immvzmpr1 Start Date*: Information not available in EudraCT
    Sponsor Name:Västra Götalandsregionen
    Full Title: A clinical study to examine cellular and humoral immunity against measles and chickenpox in children and adolescents 0-18 years in childhood cancer.
    Medical condition: This study will be conducted as a longitudinal study. Former studies have shown that immunity is affected after treatment against childhood cancer. We want to investigate humoral and cell-mediated ...
    Disease:
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-002828-33 Sponsor Protocol Number: ICRC-ICIT-01 Start Date*: 2012-10-10
    Sponsor Name:Fakultní nemocnice u sv. Anny v Brně
    Full Title: RANDOMIZED, MULTICENTRIC STUDY COMPARING THE EFFECT OF TWO REGIMENS OF COMBINED IMMUNOSUPPRESIVE THERAPY IN THE TREATMENT OF INFLAMMATORY CARDIOMYOPATHY CZECH-ICIT (CZECH INFLAMMATORY CARDIOMYOPATH...
    Medical condition: Patients with endomyocardial biopsy (EMB) proven inflammatory cardiomyopathy (ICM) defined by EMB established presence of myocardial inflammation and absence of cardiotropic infectious agents estab...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2017-000820-83 Sponsor Protocol Number: NNL-2017 Start Date*: 2017-07-03
    Sponsor Name:University of Oulu
    Full Title: Otitis Media and Nasopharyngeal Microbiome in Children. The change of nasopharyngeal microbiome and its role as a risk factor of otitis media. Streptococcus salivarius K12 and the change of nasop...
    Medical condition: We investigate role of microbiota as the risk factor of acute otitis media in children.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10033071 Otitis LLT
    20.1 100000004862 10069718 Bacterial colonization LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2024-000341-27 Sponsor Protocol Number: DEN-324 Start Date*: 2024-12-13
    Sponsor Name:Takeda
    Full Title: A Randomized, Double-Blind, Placebo-Controlled (Participants aged 18 to 60 years) and Open-Label (Participants aged 4 to 17 years), Phase 2/3 Trial to Evaluate the Immunogenicity and Safety of 2 do...
    Medical condition: Dengue fever
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10012312 Dengue fever virus infection LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2015-001396-40 Sponsor Protocol Number: R668-AD-1434 Start Date*: 2015-10-01
    Sponsor Name:Regeneron Pharmaceuticals, Inc.
    Full Title: An open-label extension study to assess the long-term safety and efficacy of dupilumab in patients ≥6 months to <18 years of age with atopic dermatitis
    Medical condition: Atopic dermatitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004858 10003639 Atopic dermatitis LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned) DE (Trial now transitioned) PL (Trial now transitioned) GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2020-003877-23 Sponsor Protocol Number: IMPROVE-MC Start Date*: 2022-03-22
    Sponsor Name:Medical University of Warsaw
    Full Title: A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of immunosuppression in biopsy-proven virus negative myocarditis or inflammatory cardiomyopathy (IMPROVE-...
    Medical condition: Myocarditis, inflammatory cardiomyopathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10028606 Myocarditis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-003350-41 Sponsor Protocol Number: APOCT-003 Start Date*: 2017-03-28
    Sponsor Name:Division pf Paediatric and Adolescent Medicine, Oslo University Hospital
    Full Title: The Diabetes Virus Detection and Intervention Trial (DiViDIntervention)
    Medical condition: Newly diagnosed Type 1 Diabetes diagnosed within the previous three weeks at time of screening. Female and male patients between the ages of 6 and 15 years will be recruited.
    Disease: Version SOC Term Classification Code Term Level
    19.1 10027433 - Metabolism and nutrition disorders 10067584 Type 1 diabetes mellitus PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NO (Completed) SE (Ongoing) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004111-37 Sponsor Protocol Number: BHC-ABT-001 Start Date*: 2014-10-22
    Sponsor Name:BUDAI HEPATOLÓGIAI CENTRUM
    Full Title: Individual Patient Access to AbbVie ABT-450/rítonavir/ABT-267 and ABT 333 Coadministered witb Ribavirín (RBV) in Patient with Genotype 1 Hepatitis C Vírus Infection witb Cirrhosis
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    17.0 10021881 - Infections and infestations 10019744 Hepatitis C PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-001096-39 Sponsor Protocol Number: MV25600 Start Date*: 2012-07-10
    Sponsor Name:F.Hoffmann-La Roche Ltd.
    Full Title: An International, Multi-Center Study Evaluating the Correlation of IL28B Genotypes with Chronic Hepatitis C Disease Characteristics and Patient Demographics
    Medical condition: Chronic hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C LLT
    14.1 10022891 - Investigations 10019752 Hepatitis C virus (HCV) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-005453-13 Sponsor Protocol Number: EGRADICATE Start Date*: 2016-08-03
    Sponsor Name:Fundació clínic per a la Recerca Biomèdica
    Full Title: PILOT STUDY TO EVALUATE THE EFFICACY AND TOLERABILITY OF GRAZOPREVIR + ELBASVIR FOR 12 OR 16 WEEKS IN LIVER TRANSPLANT RECIPIENTS
    Medical condition: HCV infection and liver trasplant
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004848 10019752 Hepatitis C virus (HCV) LLT
    19.0 100000004865 10024716 Liver transplantation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2023-000134-15 Sponsor Protocol Number: DEN-302 Start Date*: 2023-09-22
    Sponsor Name:Takeda
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Investigate the Safety and Immunogenicity of a Dengue Tetravalent Vaccine (Live, Attenuated) (TDV) Administered Subcutaneously to He...
    Medical condition: Dengue Fever
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10012310 Dengue fever PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2014-000672-25 Sponsor Protocol Number: MK-5172-059 Start Date*: 2014-12-31
    Sponsor Name:Merck Sharp & Dohme Copr., a subsidary of Merck & Co.
    Full Title: A Phase II/III Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects with Chronic Hepatitis C Virus Infection with Advanced Cirrhosis and Chi...
    Medical condition: Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004848 10019751 Hepatitis C virus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Prematurely Ended) ES (Prematurely Ended) NL (Completed) EE (Completed) PL (Completed) IT (Prematurely Ended) GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-009214-40 Sponsor Protocol Number: A8121014 Start Date*: 2009-07-08
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF FILIBUVIR PLUS PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN IN TREATMENT NAÏVE, HCV GENOTYPE 1 INF...
    Medical condition: Treatment of chronic HCV genotype 1 infection.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10019752 Hepatitis C virus (HCV) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) FR (Completed) ES (Completed) BE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-004009-15 Sponsor Protocol Number: VIS410-203 Start Date*: 2017-07-03
    Sponsor Name:Visterra, Inc.
    Full Title: Phase 2b, Multicenter, Randomized, Double-blind, Controlled Study to Evaluate the Efficacy and Safety of Intravenous VIS410 in Addition to Oseltamivir (Tamiflu®) Compared With Oseltamivir Alone in ...
    Medical condition: Influenza A infection in hospitalized patients who need supplemental oxygen
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004862 10022002 Influenza A virus infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) BG (Completed) EE (Completed) LV (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-000836-27 Sponsor Protocol Number: AI444-026 Start Date*: 2011-09-30
    Sponsor Name:Bristol Myers Squibb International Corporation
    Full Title: An Open-Label Re-treatment Study with Peg-Interferon Alfa-2a, Ribavirin and BMS-790052 With or Without BMS-650032 for Subjects With Chronic Hepatitis C Revised Protocol Number 05; Incorporates Ame...
    Medical condition: HEPATITIS C VIRUS
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004848 10019752 Hepatitis C virus (HCV) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) GB (Completed) ES (Completed) SE (Completed) DK (Completed) IT (Completed) AT (Completed) NL (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2019-002034-36 Sponsor Protocol Number: V937-011 Start Date*: 2019-12-20
    Sponsor Name:Merck Sharp & Dohme LLC
    Full Title: A Phase 2, Randomized Clinical Study of Intravenous or Intratumoral Administration of V937 in Combination with Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants with Advanced/Metas...
    Medical condition: Advanced/metastatic melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10053571 Melanoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Completed) GB (GB - no longer in EU/EEA) ES (Completed) FR (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 31 17:30:59 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA